Rajkumar S, et al. – In this study, researchers primarily investigated how optimal cytoreduction impacts outcomes in women who have had surgical treatment for advanced stage (IIIC/IV) endometrial cancer. They also identified demographics and surgico-pathologic variables that significantly influenced survival outcomes. They analyzed records of 45 patients with stage IIIC/IV endometrial cancer who underwent surgery with cytoreductive intent between 2010 and 2016, identifying 28 women who had undergone primary surgery and 17 women who received neoadjuvant chemotherapy prior to delayed primary surgery. In 29 women, optimal cytoreduction to ≤ 1 cm visible disease was achieved. Outcomes revealed significantly better progression-free survival and overall survival rates in relation to the achievement of optimal cytoreduction. Patients who had optimal cytoreduction had a median overall survival of 29 months vs 17.5 months in women who had bulky residual disease. Multivariate analyses revealed predictors of poor survival that comprised poor performance status, presence of bowel disease, and suboptimal cytoreduction.